Bioxcel Therapeutics BTAI 深 沪
等待开盘 11-01 09:30:00 美东时间
2.035
+0.015
+0.74%
华盛通- 最 高2.06
- 今 开2.04
- 成交量 48.23万股
- 最 低 1.98
- 昨 收 2.02
- 总市值 3998.12万
- 52周最高 11.52
- 市盈率 静 --
- 换手率 2.46%
- 52周最低 1.17
- 委 比 29.29%
- 总股本 1964.68万
- 历史最高 1144.00
- 量 比 0.67
- 振 幅 3.96%
- 历史最低 1.98
- 每 手 1
- 风险率 2.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
BioXcel Therapeutics reported strong correlation results between mCGI-S and PEC scales in their SERENITY At-Home trial, supporting the effectiveness of BXCL501 in treating agitation related to schizophrenia and bipolar disorder. The findings will be included in the sNDA submission planned for Q1 2026. The study involved 33 patients and demonstrated statistically significant correlations (ρ=0.89 for patients and ρ=0.88 for informants), with no ser...
10-14 11:00
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
BioXcel Therapeutics, Inc. announced that its CEO, Vimal Mehta, Ph.D., and team will ring the Nasdaq Closing Bell on October 14, 2025. This milestone celebrates the company's progress in addressing agitation associated with bipolar disorders and schizophrenia, following the successful completion of its SERENITY At-Home pivotal trial. The event highlights BioXcel's commitment to transforming mental health care and bringing innovative treatments di...
10-13 11:00
BioXcel regains compliance with Nasdaq listing rule
BioXcel Therapeutics (NASDAQ:BTAI) has regained compliance with Nasdaq’s market value of listed securities (MVLS) requirement for continued listing on the exchange. On March 20, 2025, the company was ...
09-18 19:41
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
BioXcel Therapeutics announced it has regained compliance with Nasdaq's market value of listed securities (MVLS) requirement under Rule 5550(b)(2). The company previously fell below the $35 million threshold for 30 consecutive business days in March 2025 but received an exception after a hearing in May. Nasdaq confirmed compliance on September 17, 2025, allowing the company to continue listing on the Nasdaq Capital Market.
09-18 11:00
Bioxcel Therapeutics Files Current Report on Form 8-K
Bioxcel Therapeutics ( ($BTAI) ) has provided an announcement. Bioxcel Therapeu...
09-15 23:09
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
Mizuho Maintains Neutral on BioXcel Therapeutics, Raises Price Target to $4
Mizuho analyst Graig Suvannavejh maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Neutral and raises the price target from $2 to $4.
09-12 19:57
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients
BioXcel's Phase 3 trial shows BXCL501 effectively reduces agitation in bipolar and schizophrenia patients, supporting its at-home treatment use.
09-11 03:08
BioXcel Therapeutics Reports Positive Phase 3 Trial Results
Bioxcel Therapeutics ( ($BTAI) ) has issued an update. On September 10, 2025, B...
09-10 18:59
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BioXcel Therapeutics' CEO, Vimal Mehta, Ph.D., will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 4:30 p.m. ET. The presentation will be available via webcast. BioXcel Therapeutics utilizes AI to develop innovative medicines in neuroscience and immuno-oncology, focusing on drug re-innovation to identify new therapeutic indications. The event webcast and additional information c...
09-04 11:00
